Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We further demonstrate that exogenous expression of TCF21 in cells that have silenced the endogenous TCF21 locus resulted in a reduction of tumor properties in vitro and in vivo.
|
16415157 |
2006 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using restriction landmark genomic scanning, a recent study identified TCF21 as candidate tumor suppressor at 6q23-q24 that is epigenetically inactivated in lung and head and neck cancers.
|
18398044 |
2008 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TCF21 hypermethylation in a variety of tumor cell lines suggests it may also be a valuable methylation biomarker in other tumor types.
|
20945327 |
2011 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transcription factor 21 (TCF21) belongs to the class A of the basic helix-loop-helix family with reported functions in early lung and kidney development as well as tumor suppressor function in the malignancies of the lung and head and neck.
|
21771727 |
2011 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transcription factor 21 (TCF21) has been identified as a candidate tumor suppressor at 6q23-q24 that is epigenetically inactivated in many types of human cancers.
|
22862160 |
2012 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The methylation frequencies of TCF21 were found to be significantly higher in tumors of patients without nicotine abuse (p = 0.030), in HPV-positive tumors (p = 0.014) and in tumors exhibiting over-expression of p16, a protein induced by HPV (p = 0.006).
|
23529585 |
2013 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Long noncoding RNA TARID directs demethylation and activation of the tumor suppressor TCF21 via GADD45A.
|
25087872 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transcription factor 21 (TCF21) has been identified as a candidate tumor suppressor at 6q23-q24 that is epigenetically inactivated in many types of human cancers.
|
25156819 |
2015 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, the low expression of TCF21 mRNA was associated with large tumor size and positive lymph node metastasis.
|
26044559 |
2015 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Integrated analysis of expression and methylation data identified promoter hypermethylation and low expression of the tumor suppressor gene TCF21 (Pod-1/capsulin/epicardin) in all CCSKs except the case with t(10;17)(q22;p13).
|
26158413 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, demethylation treatment resulted in re-expression of TCF21 in CRC cell lines, and cellular function experiments revealed that restoration of TCF21 inhibited CRC cell proliferation, promoted apoptosis and suppressed cell invasion and migration, suggesting that TCF21 may function as a tumor suppressor gene, which is downregulated through promoter hypermethylation in CRC development.
|
26435499 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transcription factor 21 (TCF21) functions as a tumor suppressor and is inactivated in several types of cancer.
|
27270650 |
2016 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, TCF21 functions as a tumor suppressor probably through inactivation of PI3K/AKT signaling and inhibition of MMPs.
|
28352192 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, these findings support the hypothesis that Transcription Factor 21 is a regulator of steroidogenic factor 1 and is a tumor suppressor gene in pediatric and adult adrenocortical tumors.
|
28658440 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BACKGROUND The transcription factor 21 (TCF21) gene is believed to be a tumor suppressor gene.
|
28663539 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor suppressor function of TCF21 has not been functionally addressed in ccRCC cells; we aimed to explore the functional potential of TCF21 expression in ccRCC cells in vitro.
|
29080283 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found that the expression of TCF21 was significantly regulated by its methylation level in patients with NSCLC and was associated with tumor stage, metastasis and invasion.
|
29086202 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, we propose using the subtracted expression levels of the <i>TCF21/POD-1</i> genes as a predictor of overall survival (OS) in adult carcinomas and <i>TCF21-NR5A1</i> as a predictor of malignancy for pediatric tumors in patients aged <5 years.
|
29520253 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
After controlling for potentially relevant confounding variables such as patient comorbidities, tumor size, and location, lower extremity soft tissue sarcomas (p = 0.002, odds ratio [OR], 6.4; 95% confidence interval [CI], 1.97-20.84) and elevated POD 1 early morning blood sugars (p < 0.001; OR, 1.1; 95% CI, 1.04-1.11) were associated with increased wound complications postoperatively.
|
29529645 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall, our study determined that TCF21, a hypoxia-driven p53 target, functions as a tumor suppressor in UCEC and presents as a therapeutic target for tumor treatment.
|
29608330 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, mechanistic studies showed that with TCF21 gene overexpressed, the expression of tumor suppressor Kiss-1 was upregulated and epithelial-mesenchymal transition (EMT) related proteins (E-cadherin, N-cadherin, Snail, Twist, and Vimentin) which participate in cancer cell invasion and metastasis, were reversed.
|
29909422 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Studying the tumor suppressor TCF21 (ref.
|
30617255 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present study, we define clinical stratification of HGSC tumors through the establishment of standard operating procedures for immunohistochemistry and histochemistry based detection of a panel of biomarkers including TCF21, E-cadherin, PARP1, Slug, AnnexinA2, and hyaluronan.
|
30857227 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients with good functional status can be safely discharged on POD1 after tumor craniotomy if the appropriate postoperative criteria have been met.
|
30862575 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Ectopic expression of TCF21 in CCA cells inhibited xenograft growth or tumor-associated angiogenesis in vivo and targeted the expression and secretion of proangiogenic factors, VEGFA and PDGF-BB.
|
30920845 |
2019 |